63720-38-7

Usage

Uses

Used in Pharmaceutical Industry:
3-(1-aminoethyl)phenol is used as a key intermediate in the synthesis of roxadustat, a drug that is used to stimulate the production of hemoglobin and red blood cells. Roxadustat is a hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, which helps in the treatment of anemia associated with chronic kidney disease (CKD) by promoting the production of erythropoietin, a hormone that stimulates red blood cell production.
In the synthesis of roxadustat, 3-(1-aminoethyl)phenol plays a crucial role as a reactant, contributing to the formation of the final drug molecule. Its presence in the synthesis process is essential for the development of roxadustat, which has been shown to be effective in improving the quality of life and overall health of patients suffering from anemia related to chronic kidney disease.
Furthermore, 3-(1-aminoethyl)phenol may also have potential applications in other areas of the pharmaceutical industry, such as the development of new drugs with different therapeutic targets or as a building block for the synthesis of other bioactive compounds. Its versatility and reactivity make it a valuable compound for researchers and chemists working in the field of medicinal chemistry and drug discovery.

Upstream product

• 121-71-1 3-Hydroxyacetophenone 
• 218900-56-2 (S)-[1-(3-methoxyphenyl)ethyl]carbamic acid tert-butyl ester 
• 50919-07-8 1-(3-methoxy-phenyl)-ethylamine 
• 34068-01-4 1-[3-(phenylmethoxy)phenyl]ethan-1-one 
• 50919-07-8 (S)-1-(3-methoxyphenyl)ethylamine 
• 2454-35-5 3-acetylphenyl acetate 

Downstream Products

• 127517-74-2 5-amino-4-chloro-6-<<1-(3-hydroxyphenyl)ethyl>amino>pyrimidine 
• 53389-75-6 N-Chloracetyl-1-(3-hydroxy-phenyl)-aethylamin 
• 127517-76-4 6-chloro-9-<1-(3-hydroxyphenyl)ethyl>-9H-purine 
• 127517-67-3 1,9-dihydro-9-<1-(3-hydroxyphenyl)ethyl>-6H-purin-6-one 
• 127517-68-4 1,9-dihydro-9-<1-(3-hydroxyphenyl)ethyl>-6H-purine-6-thione 
• 127517-69-5 9-<1-(3-hydroxyphenyl)ethyl>-6-(methylthio)-9H-purine 
• 127517-66-2 6-(dimethylamino)-9-<1-(3-hydroxyphenyl)ethyl>-9H-purine 
• 127517-71-9 9-<1-(3-acetoxyphenyl)ethyl>-1,9-dihydro-6H-purin-6-one 
• 127517-72-0 9-<1-(3-acetoxyphenyl)ethyl>-6-(methylthio)-9H-purine 
• 127517-70-8 9-<1-(3-acetoxyphenyl)ethyl>-6-(dimethylamino)-9H-purine 
• 105601-04-5 (+/-)-3-<1-(Dimethylamino)ethyl>phenol 
• 1105678-30-5 3-{[1-(3-hydroxyphenyl)ethyl]amino}-4-(pyridin-4-ylamino)cyclobut-3-ene-1,2-dione 
• 63720-38-7 3-hydroxy-(S)-α-phenethylamine 
• 477312-35-9 (S)-[1-(3-morpholin-4-yl-phenyl)ethyl]-carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

Method for separating chiral amine compound and intermediate thereof

The present invention discloses a method for separating a chiral amine compound and an intermediate thereof. The method comprises the following steps: salt forming reaction of the chiral amine compounds and a resolving agent in a solvent; the chiral amine compound is 3-(1-aminoethyl) phenol, (2R, 3S) 4-amino-1, 2, 3-cyclopentyl triol or trans-cyclohexanediamine; the resolving agent is L-alpha-amino acid, an L-alpha-amino acid derivative, D-alpha amino acid or a D-alpha amino acid derivative; the method can be used for better separation of the chiral amine compound, the method has high yield and low cost, and is suitable for industrialized production.

Method for Preparing an Optically Active 1-(3-hydroxyphenyl)ethylamine

PURPOSE: A producing method of optically active 1-(3-hydroxyphenyl)ethylamine with the optical activity is provided to economically mass produce the 1-(3-hydroxyphenyl)ethylamine. CONSTITUTION: A producing method of optically active 1-(3-hydroxyphenyl)ethylamine comprises a step of reacting racemic 1-(3-hydroxyphenyl)ethylamine, with D-tartaric acid or L-tartaric acid to obtain semi tartarate, and a step of hydrolyzing the semi tartarate to form (S)- or (R)-1-(3-hydroxyphenyl)ethylamine.

Stereoselective Metal-Free Reduction of Chiral Imines in Batch and Flow Mode: A Convenient Strategy for the Synthesis of Chiral Active Pharmaceutical Ingredients

The convenient, metal-free reduction of imines that contain an inexpensive and removable chiral auxiliary allowed for the synthesis of the immediate precursors of chiral active pharmaceutical ingredients (APIs). This protocol was carried out under batch and flow conditions to give the correspoding products in high yields with almost complete stereocontrol. In the presence of trichlorosilane, an inexpensive and nontoxic reducing agent, and an achiral Lewis base such as N,N-dimethylformamide, the formal syntheses of Rivastgmine, calcimimetic NPS R-568, and a Rho kinases inhibitor were successfully accomplished. For the first time, both the diastereoselective imine reduction and the auxiliary removal were efficiently performed in a micro- or mesoreactor under continuous-flow conditions, which paved the way towards the development of a practical process for the syntheses of industrially relevant, biologically active, enantiopure N-alkylamines.

Biocatalysts and methods for the synthesis of (S)-3-(1-aminoethyl)-phenol

The present disclosure provides engineered transaminase polypeptides having improved properties as compared to naturally occurring transaminases including the ability of converting the substrate, 3′-hydroxyacetophenone to (S)-3-(1-aminoethyl)-phenol in enantiomeric excess and high percentage conversion. Also provided are polynucleotides encoding the engineered transaminases, host cells capable of expressing the engineered transaminases, and methods of using the engineered transaminases to synthesize (S)-3-(1-aminoethyl)-phenol and related compounds useful in the production of active pharmaceutical ingredients.

Discovery of (S,E)-3-(2-fluorophenyl)-N-(1-(3-(pyridin-3-yloxy)phenyl) ethyl)-acrylamide as a potent and efficacious KCNQ2 (Kv7.2) opener for the treatment of neuropathic pain

Acrylamide (S)-6, a potent and efficacious KCNQ2 (Kv7.2) opener, demonstrated significant activity in two models of neuropathic pain and in the formalin test, suggesting that KCNQ2 openers may be useful in the treatment of neuropathic pain including diabetic neuropathy.

PROCESS FOR PRODUCING (S)-3-[(1-DIMETHYLAMINO)ETHYL] PHENYL-N-ETHYL-N-METHYL-CARBAMATE VIA NOVEL INTERMEDIATES

Disclosed herein are novel intermediates and process for large scale production of (S)-3-[(1-dimethylamino)ethyl]phenyl-N-ethyl-N-methyl-carbamate (rivastigmine) or its pharmaceutically acceptable salts employing the novel intermediates. Further provided are methods for producing the novel intermediates thereof.

PROCESSES FOR PREPARING RIVASTIGMINE, SALTS AND INTERMEDIATES THEREOF

Processes for preparing Rivastigmine, salts and intermediates thereof are disclosed. More specifically, a process for preparing S-(-)-3-[(l -dimethylamino)ethyl]-phenol is provided.

Chemoenzymatic asymmetric total synthesis of (S)-Rivastigmine using ω-transaminases

A straightforward, high-yielding, chemoenzymatic total synthesis of enantiopure (S)-Rivastigmine was developed using various ω-transaminases for the asymmetric amination of appropriate acetophenone precursors. Optimisation of the biotransformation allowed scale-up and the total synthesis of (S)-Rivastigmine. The Royal Society of Chemistry 2010.

A PROCESS FOR PRODUCING (S)-3-[(1-DIMETHYLAMINO)ETHYL] PHENYL-N-ETHYL-N-METHYL-CARBAMATE VIA NOVEL INTERMEDIATES

Disclosed herein are novel intermediates and process for large scale production of (S)- 3-[(1-dimethylamino) ethyl] phenyl-N-ethyl-N-methyl-carbamate (rivastigmine) or its pharmaceutically acceptable salts employing the novel intermediates. Further provided are methods for producing the novel intermediates thereof.

Identification and SAR of squarate inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2)

A novel series of inhibitors for mitogen activated protein kinase-activated protein kinase 2 (MK-2) are reported. These squarate based inhibitors were identified via a high-throughput screen. An MK2 co-structure with the starting ligand was obtained and a structure based approach was followed to optimize potency and selectivity.